Initial clinical experience with a sac-anchoring endoprosthesis for aortic aneurysm repair  by Donayre, Carlos E. et al.
From the Western Vascular Society
Initial clinical experience with a sac-anchoring
endoprosthesis for aortic aneurysm repair
Carlos E. Donayre, MD,a Christopher K. Zarins, MD,b Dainis K. Krievins, MD,c Andrew Holden, MD,d
Andrew Hill, MBChB, FRACS,d Carlos Calderas, MD,e Jaime Velez, MD,f and
Rodney A. White, MD,a Torrance and Stanford, Calif; Riga, Latvia; Auckland, New Zealand; Caracas,
Venezuela; and Cali, Colombia
Objective: All current aortic endografts depend on proximal and distal fixation to prevent migration. However, migration and
rupture can occur, particularly in patients with aortic necks that are short or angulated, or both. We present our initial clinical
experience with a new sac-anchoring endoprosthesis designed to anchor and seal the device within the aneurysm sac.
Methods: The initial worldwide experience using a new endoprosthesis for the treatment of aortic aneurysms (Nellix
Endovascular, Palo Alto, Calif) was reviewed. The endoprosthesis consists of dual balloon-expandable endoframes
surrounded by polymer-filled endobags designed to obliterate the aneurysm sac andmaintain endograft position. Clinical
results and follow-up contrast computed tomography (CT) scans at 30 days and 6 and 12 months were reviewed.
Results: The endograft was successfully deployed in 21 patients with infrarenal aortic aneurysms measuring 5.7 0.7 cm
(range, 4.3-7.4 cm). Two patients with common iliac aneurysms were treated with sac-anchoring extenders that
maintained patency of the internal iliac artery. Infusion of 71  37 mL of polymer (range, 19-158 mL) into the aortic
endobags resulted in complete aneurysm exclusion in all patients. Mean implant time was 76 35 minutes, with 33 17
minutes of fluoroscopy time and 180  81 mL of contrast; estimated blood loss was 174  116 mL. One patient died
during the postoperative period (30-day mortality, 4.8%), and one died at 10 months from non-device-related causes.
During amean follow-up of 8.7 3.1months and amedian of 6.3months, there were no late aneurysm- or device-related
adverse events and no secondary procedures. CT imaging studies at 6 months and 1 year revealed no increase in aneurysm
size, no device migration, and no new endoleaks. One patient had a limited proximal type I endoleak at 30 days that
resolved at 60 days and remained sealed. One patient has an ongoing distal type I endoleak near the iliac bifurcation, with
no change in aneurysm size at 12 months.
Conclusion: Initial clinical experience with this novel intrasac anchoring prosthesis is promising, with successful aneurysm
exclusion and good short-term results. This new device platform has the potential to address the anatomic restrictions and
limitations of current endografts. Further studies with a longer follow-up time are needed. (J Vasc Surg 2011;53:574-82.)
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pIn 1989, Dr Juan Parodi ushered in the era of endovas-
cular aneurysm repair (EVAR) as a less invasive alternative
to open surgical repair.1 Using a transfemoral, endoluminal
approach, he delivered a standard prosthetic surgical graft
From the Harbor/UCLA Medical Center, Torrance;a Stanford University
Medical Center, Stanford;b Pauls Stradins Clinical University Hospital,
Riga;c Auckland City Hospital, Auckland;d Instituto de Clinicas y Urolo-
gia Tamanaco, Caracas;e and Clinica Los Remedios de Cali, Cali.f
The Nellix Corporation provided support for this trial by providing endo-
prostheses to the participating international centers. It also paid for the
costs involved in data gathering at each participating center. Along with all
the listed authors, it participated in the design of this study. Manuscript
writing as well as the decision to submit this manuscript for publication
was the decision of the listed authors.
Competition of interest: Carlos Donayre, Rodney White, and Christopher
Zarins are members of the Nelllix Scientific Advisory Board, for which
they have been awarded stock options. Carlos Donayre and RodneyWhite
have also received research funding from Nellix Corporation. Dainis
Krievins, AndrewHolden, AndrewHill, Carlos Calderas, and Jaime Velez
received funding for being a clinical coordinator from the Nellix Corpo-
ration.
Presented at the Twenty-fourth Annual Meeting of the Western Vascular
Society, Tucson, Ariz, Sep 19-22, 2009.
Correspondence: Carlos E. Donayre, MD, Division of Vascular and Endo-
vascular Surgery Harbor/UCLA Medical Center, 1000 W Carson St,
Torrance, CA 90502 (e-mail: cdonayre@cox.net).
The editors and reviewers of this article have no relevant financial relationships
to disclose per the JVS policy that requires reviewers to decline review of any
manuscript for which they may have a competition of interest.
0741-5214/$36.00n
Copyright © 2011 by the Society for Vascular Surgery.
doi:10.1016/j.jvs.2010.09.009
574nto the aneurysm sac and used a balloon-expandable stent
o attach it to the nonaneurysmal infrarenal aortic neck.
lthough the concept of transfemoral endoluminal delivery
f a prosthetic aortic graft was revolutionary, the principle
f EVAR was similar to open repair. Both procedures
nvolved attachment of the prosthetic graft to nonaneurys-
al aortic neck proximally and to the normal aorta or iliac
rteries distally, and the success of the aneurysm repair
epended on the security and durability of the graft attach-
ent.
Although the less invasive procedure of EVAR using
urrently available devices has markedly reduced procedur-
lly related mortality and morbidity compared with open
epair,2,3 significant concerns persist regarding the long-
erm durability and effectiveness of EVAR. Endograft mi-
ration, endoleaks, aneurysm enlargement, and the need
or secondary procedures to prevent rupture are cause for
ontinuing concern.4-7
All currently available endografts share similar design
eatures such as a bifurcated fabric-stent construct with
roximal and distal attachment zones to provide fixation
nd seal to nonaneurysmal aorta and iliac arteries. A great
eal of attention has been focused on the infrarenal aortic
eck as the focal point for patient selection, endograft
izing, positioning, fixation, and sealing. The importance of
roximal fixation in preventing migration is well recog-
ized,8,9 and a variety of strategies have been used in
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Volume 53, Number 3 Donayre et al 575current U.S. Food and Drug Administration (FDA)-
approved devices, including suprarenal stents, hooks, barbs,
radial force, and columnar support. These are supported by
in vitro experimental studies using linear pull-out force
analysis that demonstrate increased resistance to longitudi-
nal endograft displacement by penetrating hooks and
barbs.10 In addition, in vivo experimental studies11 have
shown that iliac fixation increases the resistance to down-
ward displacement, and clinical studies have confirmed the
importance of iliac fixation in preventing migration.8-11
Nonetheless, migration has been reported with each of the
currently available EVAR devices, regardless of the proxi-
mal and distal fixation mechanisms.12,13
In contrast, little attention has been focused on the
middle portion of the endograft, which is unsupported
within the aneurysm sac. Aneurysm sac diameter reduction
and shrinkagemay lead to device fractures and tears. Rafii et
al14 recently showed that lateral movement of the en-
dograft within the aneurysm sac, as seen on cross-sectional
computed tomography (CT) scan images at 1 year, was an
indicator of endograft instability and late adverse clinical
events. In addition, the risk of lateral endograft movement
was higher in patients with large aneurysms.
Three-dimensional (3D) computational analysis has re-
vealed that the in vivo displacement force acting on en-
dografts is not in the downstream direction of blood flow,
as is commonly assumed, but rather is in a lateral or
sideways direction perpendicular to the direction of flow.15
None of the commercially available aortic stent grafts are
designed to oppose this lateral displacement force and all
are prone to device migration.4-15
We describe a new endovascular aneurysm device de-
signed to withstand the lateral displacement forces acting
on endografts, while at the same time obliterating the
aneurysm sac lumen. The device consists of two indepen-
dent flow channels, one to each iliac artery. Each flow
channel is surrounded by a polymer-filled bag that expands
to fill the aneurysm sac, thus providing positional stability
of the endograft and sealing side branch flow.16 This article
describes the initial, worldwide clinical experience, outside
the United States, using this new endovascular device for
the treatment of aortic aneurysms.
METHODS
Device description. The Nellix sac-anchoring endo-
prosthesis (Nellix Endovascular, Palo Alto, Calif) consists
of two identical catheter-based systems, one for each side.
Each system has four components:
1. The endoframe: This is a stainless steel, balloon-
expandable endoskeleton designed to support the flow
channel that is mounted on a balloon and deployed by
inflating the balloon. Two endoframes are positioned in a
kissing configuration at the aortic neck proximally and
each extends into the common iliac artery distally.
2. The endobag: This is made from a nonporous expanded
polytetrafluoroethylene-based material that surrounds
the endoframe and acts as a containment system for the ipolymer, which fills and conforms to the aneurysm sac
providing a seal at the aortic and iliac ends. An injection
system accesses the bottom of the endobag through fill
conduits and valves, including a mechanical safety
mechanism to prevent accidental delivery of uncured
polymer into the bloodstream.
. Fill material or polymer: This is a biocompatible,
nonbiodegradable polyethylene glycol-based solu-
tion, mixed with a radiopaque contrast agent that is
visible under fluoroscopy and cures to a solid 5 min-
utes at 37°C. Filling is achieved by an injection system
that includes a handle with a controlled mechanism to
monitoring fill volume and pressure.
. Delivery catheter: The current tapered-nose cone deliv-
ery system has an outer diameter of 21F and contains the
balloon-mounted endoframe with surrounding endo-
bag and conduits for fill material injection, along with
ports for guidewire insertion, balloon inflation, and
angiography. Device components in the undeployed
state and after deployment inside a synthetic aneurysm
model are shown in Fig 1.
Animal studies. Before the clinical studies were initi-
ted, extensive bench and animal studies were conducted.
inite-element stress analysis was used to ensure that endo-
rame design would withstand loads from balloon expan-
ion, endobag filling, and intra-arterial blood pressure load-
ng. The device was tested in vitro for long-term durability
quivalent to 10 years of in vivo life. The deployment
ystem was tested in flow models using realistic human
neurysmmodels that simulated the conditions of intended
linical use.
Animal studies were conducted in a patch-aneurysm
vinemodel to evaluate the safety of the device delivery and
eployment system and the success of aneurysm exclusion.
ong-term results, with animals surviving 2 years,
howed effective long-term aneurysm exclusion and lumen
atency as demonstrated on CT and angiographic imaging.
istologic studies showed minimal trauma and low inflam-
ation.16
Clinical experience. The initial clinical experience us-
ng the Nellix endoprosthesis at four international medical
enters in Latvia, New Zealand, Venezuela, and Colombia
uring the past 2 years was reviewed. The study protocol
as approved by the Institutional Review Board at each
linical site, and each patient signed an approved informed
onsent written in his or her native language.
Preoperative, implant, and follow-up data were col-
ected real-time according to prospectively defined proto-
ol parameters. All patients were deemed to be appropriate
andidates for open aortic aneurysm repair with suitable
natomy for endovascular repair using the sac-anchoring
ndoprosthesis. Patients with iliofemoral arteries unable to
ccommodate a 21F outer diameter delivery catheter were
xcluded. All patients were studied with preoperative con-
rast CT scans with 1- to 3-mm slice thickness and 3D
mage analyses. If anatomic criteria were met, they were
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March 2011576 Donayre et alenrolled into the study after signing institutionally ap-
proved informed consent.
All team members involved with the clinical device
deployment underwent didactic and hands-on training us-
ing patient-specific silicone cast aneurysm flow models be-
fore undertaking patient treatment. At least one investiga-
tor at each clinical deployment had extensive prior in vivo
experience with the device in experimental animal aneu-
rysm models before human implantation experience.
Procedure. Bilateral transfemoral sheath and 0.035-
inch guidewire access was obtained using standard surgical
techniques. Under fluoroscopic and angiographic control,
the device delivery catheters were advanced and positioned
across the aneurysm sac. The covering sheath was retracted,
and the catheters were positioned at the desired location
with respect to the renal arteries. The endoframes were
expanded by simultaneous inflation of the deployment
Fig 1. Images of the Nellix sac-anchoring abdominal aortic an-
eurysm device. A, A single catheter is shown in the undeployed
state.B,Two catheters have been deployed in a synthetic aneurysm
model.balloons. Both endobags were then filled with contrast- (nhanced saline under fluoroscopic guidance while the
ressure inside the endobag was monitored. This deter-
ined the volume required to completely fill the aneurysm
ac.
An aortogram using subtraction angiography was ob-
ained with the endobags filled to confirm that the aneu-
ysm had been successfully excluded. The contrast solution
as aspirated from the endobags. The endobags were then
lled by injecting the same volume of polymer under fluo-
oscopy and pressure control. Endobag fill pressures were
ithin the range of physiologic blood pressure, with amean
ll pressure about 50 mm Hg greater than the patient’s
ystolic pressure, not 200 mm Hg. After 5 minutes, the
olymer was cured, and the delivery catheters were released
rom the implant and removed from the patient. A comple-
ion aortogram was obtained. A typical deployment se-
uence is shown in Fig 2.
Nellix aortic devices were available in various sizes and
engths to treat aortic neck diameters of 22 to 28 mm, iliac
iameters of 8 to 12 mm, sac lengths between 130 and 150
m, and aneurysm blood lumen diameters of 60 mm,
ndependent of sac diameter. Nellix iliac extender devices
ere able to treat iliac aneurysms with blood lumen diam-
ters of30 mm independent of sac diameter and available
n 60-mm length. Fillable Nellix extender devices were not
vailable during the beginning of this clinical experience.
herefore, commercially available iliac extenders were used
n patients who needed distal iliac extenders during the
nitial phase of this clinical study.
Patients were monitored postoperatively with clinical
valuation and noncontrast CT scans and at 1, 6, and 12
onths.
ESULTS
Patient population. Results for 21 patients (19 men,
women) were collected, representing the entire world-
ide clinical experience to date using the Nellix device.
atients were a mean age of 69.7 8.3 years (range, 53-84
ears). All patients were deemed to be suitable candidates
or open surgical repair (Table I). Preoperative aneurysm
iameter was 5.7  0.7 cm (range, 4.3-7.4 cm), with
neurysm blood lumen diameter of 4.0  0.6 cm (range,
.0-5.0 cm). Infrarenal aortic neck diameter was 25.7 
.7 mm (range, 16-28 mm), with a neck length of 24.9 
4.3 mm (range, 0-59 mm); neck angle was 39°  15°
range, 10°-66°). Common iliac diameter was 20 mm in
4 patients,25 mm in 4, and 6 had bilateral iliac enlarge-
ent 20 mm.
Device implantation. Nellix endoprostheses were
uccessfully implanted in all 21 study patients. The time
equired to insert, implant, and remove the Nellix devices
veraged 76  35 minutes (range, 33-139 minutes; Table
I). Fluoroscopy time averaged 33  17 minutes (range,
7-71 minutes), with contrast use averaging 180 81 mL
range 110-350 mL). Mean blood loss was 174 116 mL
range, 65-400 mL). The mean total volume of polymer
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Volume 53, Number 3 Donayre et al 577infused into the endobags was 71 37 mL (range, 19-158
mL). There were no access problems or iliac injuries. In
three patients, commercially available iliac extenders were
used, and in two patients, common iliac aneurysms were
treated with Nellix sac-anchoring iliac extenders. The en-
dobag in one patient covered and excluded a hypogastric
artery, without any clinical consequence.
The treatment of a large aneurysm with minimal
thrombus and a large blood-lumen volume is shown in Fig
3. The aneurysm was treated with two devices deployed
side-by-side, each with its own lumen. The top images are
3D reconstructions before and after treatment, and the
bottom images are cross-sectional images at various times.
Preoperative CT scan measurements included a maximum
aneurysm sac diameter of 6.6 cm and aneurysm blood
lumen diameter of 5.7 cm. Aortic neck diameter was 18
mm, common iliac diameter was 12 mm, and predicted
total endobag fill volume was 133 mL. The endoframes
Fig 2. Procedural steps to treat aneurysms using the
Table I. Patient demographics and comorbidities
Variable No. (%) Mean (range)
Patients, total 21
Age, y 69.7 (53-84)
Gender
Male 19 (90.5)
Female 2 (9.5)
Hypertension 15 (71)
CAD (MI/stent) 11 (52)
CABG 2 (10)
Renal insufficiencya 1 (5)
Diabetes 2 (10)
Smoking 12 (57)
CABG, Coronary artery bypass grafting; CAD, coronary artery disease;MI,
myocardial infarction.
aDefined as a serum creatinine level 2 mg/dL.were expanded by two lumen-shaper balloons, and each sndobag was filled with 74 mL of polymer (total polymer
nfused was 148 mL). Completion angiogram demon-
trated complete aneurysm exclusion. Postprocedural CT
cans to the 1-year follow-up revealed no change in aneu-
ysm size, stable device and endobag position, and gradual
issolution of contrast from the polymer.
The treatment of a 6.4-cm aneurysm with a sharply
ngulated aortic neck is shown in Fig 4. The endoprosthesis
as positioned at the top of the aneurysm sac rather than
xtending it to the level of the renal arteries to avoid the
eck angulation. Conventional abdominal aortic aneurysm
AAA) stent grafts require device placement in the neck,
elow renal arteries, for aortic fixation. Here, the endo-
rames were held in place by the polymer-filled endobags,
nd the completion angiogram demonstrated complete
neurysm exclusion with no endoleak. The CT scan at 30
ays demonstrated contrast filling of a small portion of the
roximal aneurysm sac just below the aortic neck. This
ix sac-anchoring abdominal aortic aneurysm device.
able II. In-hospital outcomes
ariable No. (%) Mean (range)
atients, total 21
ortality
30 days 1 (4.8)
1 year 0 (0.0)
onversion to surgery 0 (0.0)
otal procedure time, minutes 127 (80-148)
ellix indwelling time, minutes 76 (33-139)
luoroscopy time, minutes 33 (13-71)
ontrast volume, mL 180 (110-350)
mount of polymer infused, mL 71 (19-158)
stimated blood loss, mL 174 (50-400)
ength of stay, days
Hospital 4.3 (2-11)
Intensive care unit 0.7 (0-3)pontaneously sealed, with no evidence of a type I endoleak
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March 2011578 Donayre et alon multiplane angiography at 60 days and no evidence of
endoleak on contrast CT at 6 months.
The treatment of a 3-cm common iliac aneurysm with
preservation of the hypogastric artery is shown in Fig 5.
After deployment of the aortic endoprosthesis and removal
of the Nellix delivery system, the distal end of the endo-
frame was flared using a 20-mm noncompliant balloon. A
Nellix iliac extender endoframe was deployed, and the
surrounding endobag was filled with polymer. This ex-
cluded the common iliac aneurysm and preserved blood
flow to the internal iliac artery.
Obliteration of retrograde branch flow into the aneu-
rysm sac is shown in Fig 6. The filled endobag expands to
obstruct the orifices of the inferior mesenteric and lumbar
arteries, thus significantly reducing the likelihood of type II
endoleaks.
Early results. Twenty of 21 patients (95%) recovered
from the implant procedure uneventfully. One patient died
postoperatively from multisystem organ failure, for a 30-
day mortality rate of 4.8%. The patient was a 74-year-old
man with a 7.4-cm aneurysm and chronic renal insuffi-
ciency with a history of hypertension, chronic obstructive
pulmonary disease, hypertensive cardiomyopathy, and
lower extremity occlusive disease. This was the first clinical
implant using this device, and the endoframe balloon ex-
panders were kept inflated throughout the endobag infla-
tion and the prefill and polymer filling procedure, resulting
in a prolonged aortic occlusion time. The postimplant
Fig 3. A-C, Pretreatment of an aneurysm with a large b
reconstructions (preoperative and postoperative).D-G,C
6, and 12 months postoperatively.premortem imaging studies revealed an intact aneurysm, natent renal arteries, and a widely patent endoluminal
evice. The postmortem examination with device explan-
ation revealed no evidence of aneurysm or vascular rup-
ure, an intact endograft with patent lumens, intact endo-
ags, and no evidence of polymer extravasation. The
mplant procedure was modified after this first case, and in
ll subsequent patients, the endoframe deployment bal-
oons were deflated immediately after full endoframe ex-
ansion with an aortic occlusion time of 2 minutes.
Mean hospital length of stay for all patients averaged
.3 days (range, 2-11 days). No groin complications oc-
urred. One patient was rehospitalized during the first 30
ays for abdominal discomfort but was discharged in 24
ours, with resolution of symptoms and normal clinical
xamination.
Follow-up results. One patient died at 10 months of
ongestive heart failure. The CT scan at 6 months in this
atient showed no change in aneurysm size, no migration,
nd no endoleak. There have been no ruptures, migrations,
urgical conversions, or secondary interventions during the
2-month follow-up. Mean follow-up time was 7.3 10.2
onths. Postprocedural CT imaging data were available for
0 patients at 30 days and at 6 months and for 9 patients at
year. These studies demonstrated widely patent endograft
umens, intact endobags, no change in endograft position,
nd no change in aneurysm size. Aneurysm diameter was
.7  0.7 cm at 30 days, 5.7  0.7 cm at 6 months, and
.8  0.8 cm at 12 months. Volumetric analysis showed
-lumen diameter and minimal thrombus, 3-dimensional
uted tomography cross-sections preoperatively and at 1,lood
ompo change in aneurysm size.
JOURNAL OF VASCULAR SURGERY
Volume 53, Number 3 Donayre et al 579Fig 4. A, Computed tomography and angiography images of an aneurysm with adverse neck anatomy treated using
the Nellix device. B, The 30-day follow-up showed a limited type I endoleak, which was not visible on angiography at
60 days.Fig 5. Angiographic images illustrate the treatment of a common iliac aneurysm using a sac-anchoring iliac extender,
which preserved flow in the hypogastric artery, (left) before and (right) after treatment.
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March 2011580 Donayre et alIn one patient (Fig 5), the postprocedural CT scan
revealed contrast fill in the space between the endobag and the
proximal anterior wall of the aneurysm sac. This limited-
space type I endoleak was sealed on multiplane angiogra-
phy at 60 days and remained sealed on CT at 6 months.
A distal type I endoleak was seen at time of implanta-
tion in one patient. This patient had a long aneurysm sac,
and the endobag lengths were too short to reach the
common iliac arteries. This was early in our experience
when Nellix iliac extenders were not available. Therefore,
commercially available iliac extenders were deployed in
both limbs. Retrograde flow from uncovered lowermost
lumbar arteries filled the bottom portion of the aneurysm
sac. This distal type I endoleak was visible on the 30-day,
6-month, and 12-month CT scan (Fig 7). The patient
Fig 6. Angiographic images (left) before and (right) aft
illustrating the occlusion of lumbar and mesenteric arte
traditional devices.
Fig 7. Angiographic and cross-sectional computed tomo
region where a commercial extender was used.remains asymptomatic, and the aneurysm size has not fhanged. Endovascular repair of this endoleak is currently
eing entertained. No other endoleaks have been seen
uring the follow-up period.
In 4 of the first 10 patients, the 30-day follow-up CT
cans revealed a non-contrast-enhanced ring, or halo, im-
ediately surrounding the endoframes. At 6 months, 7
f the first 10 patients demonstrated this finding. No
linical events or aneurysm morphologic changes have
een associated with this x-ray finding. The halo was
ttributed to the larger endobag lumen diameter relative
o the endoframe. Changes were implemented to the
ndobag design, and the halo has not been seen on any
ubsequent patient CT scans. In addition, contrast
ithin the polymer was found to dissipate over time,
onsistent with the known loss of iodinated contrast
atment from an aneurysm treated using the Nellix device
which if untreated can lead to type II endoleaks with
hy images of one type II endoleak seen in the bifurcationer tre
ries,graprom polymers at variable rates, as noted by changes in
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Volume 53, Number 3 Donayre et al 581polymer contrast density on the cross-sectional images
between 30 days and 1 year (Fig 3).
DISCUSSION
The Nellix AAA endoprosthesis represents a new con-
ceptual approach to the endovascular repair of aortic aneu-
rysms. It is a sac-anchoring device that does not depend on
proximal and distal fixation to nonaneurysmal infrarenal
aorta or iliac arteries. Rather, it is held in place by polymer-
filled bags that surround the flow channels, resisting the
sideways-directed or lateral displacement forces acting on
the endograft.
Computational analysis reveals that in vivo displace-
ment force acting on aortic endografts is primarily directed
sideways, perpendicular to the direction of blood flow
rather than downstream in the direction of blood flow.15
Increased curvature of the endograft increases the magni-
tude of sideways displacement force, and patients with
angulated aortic necks and tortuous aneurysms are more
prone to endograft migration. Lateral movement of the
middle portion of an endograft within the aneurysm sac as
seen on sequential cross-sectional CT images has been
shown to be an indicator of endograft instability and a
predictor of late adverse clinical events.14
Currently available endografts are designed to resist
longitudinal displacement in the downward direction of
blood flow.10 This device is the first endovascular device
designed taking into consideration the magnitude and di-
rection of in vivo displacement forces acting on implanted
endografts. Thus, it may provide improved resistance to
long-term displacement and migration.
In addition, filling of the aneurysm sac by polymer-
filled bags obliterates the aneurysm lumen and obstructs
retrograde flow into the aneurysm sac from the inferior
mesenteric artery and lumbar arteries. Early evidence indi-
cates that this wall apposition of the endobag design has the
potential to eliminate retrograde type II endoleaks. How-
ever, it is possible that the endobag, if not properly sized to
cover the entire surface of the aneurysm sac, may not fully
obstruct and obliterate all lumbar branches, as occurred in
one patient early in this experience. In such circumstances,
retrograde lumbar artery flow fills only a small portion of
the aneurysm sac and does not pressurize the entire aneu-
rysm sac.
Similarly, flow may enter the space between the endo-
bag and the aneurysm wall from the proximal or distal
attachment zone, as occurred transiently in one patient in
this series due to placement of the device below a sharply
angulated aortic neck. This small space has a much-reduced
functional radius compared with the radius of the untreated
aneurysm, and thus, the tension experienced by the aneu-
rysm wall (proportional to the product of sac pressure times
radius, per Law of LaPlace) may be less than the tension
produced by an endoleak that pressurizes the entire sac.
Further studies are needed to determine the significance of
contrast fill of the aneurysm sac when a sac-anchoring
endoprosthesis is used. cThe third unique feature of this device is that it is not a
ifurcated endograft. Rather, each endograft flow channel
s independent of the other, thus allowing each limb of the
evice to self-select the optimum flow pathway through the
neurysm sac. This reduces angulation and tortuosity to a
inimum and raises the bifurcation of aortic flow to the
evel of the renal arteries. This may reduce iliac limb kinking
nd improve hemodynamic performance of the device;
owever, longer-term studies are needed. The fact that this
s not a bifurcation device also simplifies deployment of the
evice because additional catheter and wire manipulation is
ot needed to cannulate the docking limb and deploy the
ontralateral iliac limb. Moreover, the balloon-expandable
eployment allows for accurate device placement without the
elivery challenges associated with current self-expanding
tent grafts.
This device simplifies the treatment of common iliac
neurysms by providing a normal flow channel to the
nternal and external iliac arteries while obliterating the
neurysm sac, as shown in Fig 5. There is no need to coil
mbolize the internal iliac artery and extend the endovas-
ular device to the external iliac artery. Future modifica-
ions of the Nellix iliac extender will be able to treat internal
liac aneurysms without occluding the flow lumen.
Finally, because the device does not depend on fixation
o normal, nonaneurysmal aorta, it may provide the oppor-
unity to treat aneurysms with anatomies currently not
menable to treatment with existing FDA-approved endo-
ascular devices. Such anatomies include no-neck or
unnel-neck aneurysms, severely angulated and tortuous
natomies, large-diameter aortic necks, and common and
nternal iliac aneurysms. Although most patients in this
tudy had favorable anatomy with good proximal and distal
anding zones, some had unfavorable anatomy and were
uccessfully treated.
The unique design features of this device raise new
uestions with regard to this method of EVAR. Potential
onsiderations include the risk of pressure transmission to
he aneurysm wall causing rupture during balloon inflation
nd/or endobag filling and thrombus extrusion into adja-
ent vessels (ie, renal arteries). In addition, as with any
ther EVAR device, placement is critical, especially for the
reatment of adverse anatomies (no-neck aneurysms, angu-
ated necks) to prevent bag prolapse into the lumen; the
issing balloon-expandable platform requires different siz-
ng considerations compared with current EVAR devices,
nd dual device extensions would be required with this
latform to achieve a secure seal in the event of a persistent
roximal type I endoleak.
Long-term remodeling of the aneurysm and mural
hrombus, stability of the polymer-filled endobag, and the
otential for late endoleaks in the space between the endo-
ag and aneurysm wall must be evaluated. Although some
f these aspects have beenmitigated through device design,
ll pressure control within the physiologic range, redun-
ant fill system designs, and physician training, more stud-
es and long-term follow-up data, including morphologic
hanges in well-controlled clinical trials, are needed.
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The initial clinical experience with a new, sac-anchoring
endoprosthesis is promising, with successful aneurysm ex-
clusion and good short-term results. This new device has
the potential to address the limitations of current en-
dografts and may provide improved long-term device sta-
bility. Further studies and longer clinical follow-up are
needed.
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